Google
KALV — KALVISTA PHARMACEUTICALS INC (Healthcare >> Biotechnology)
KALV FAQ
What is KALV's ROE?
KALVISTA PHARMACEUTICALS INC reports a Return on Equity (ROE) of 6,059.98%.
What is KALV's dividend yield?
KALVISTA PHARMACEUTICALS INC offers a dividend yield of 0.00%.
What is KALV's Deepscope Quality Score?
Deepscope rates KALV's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy KALV?
Deepscope's AI Timing Score for KALV is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does KALV belong to?
KALVISTA PHARMACEUTICALS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 26.95
Price
0.00
(0.00%)
Day Change
|
|
|---|
KALV, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROAが低い
ROEの伸びが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 85 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 26.95 |
| PBV / Sector |
-502.38 / 4.58
|
| Earning Per Share | -3.23 |
| PE / Sector |
N/A / 17.10
|
| PEG or PE/Growth / Sector |
N/A / 0.52
|
| Average 1M Daily Value |
87.28 M
|
| Average 1W Daily Value |
68.39 M
|
| Timing Factors |
|
71% |
| Financial Health |
|
37% |
| ポイントになる統計 |
|
52% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-05 09:12:02 |
| Symbol | KALV |
| Name | KALVISTA PHARMACEUTICALS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 53.24 M |
| Par Value | N/A |
| Calculated From | YearEnd |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,361.95 / 8,655.90 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 200 Crossing Boulevard, Framingham, MA, United States, 01702
Phone: 857 999 0075
Website: https://www.kalvista.com
Employees: 275
Sector: Healthcare >> Biotechnology
Description: KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of acute attacks of hereditary angioedema (HAE). The company is also developing is developing an orally disintegrating tablet formulation; KONFIDENT-KID for pediatric use with HAE; KONFIDENT; and KONFIDENT-S to evaluate sebetralstat and ODT formulation in adolescent and adult patients. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
